

Evofem Biosciences to Report Third Quarter 2021 Results and Provide Corporate Update on Monday, November 15, 2021

-- Conference Call Scheduled for 4:30 p.m. ET --

SAN DIEGO, Oct. 28, 2021 /[PRNewswire](#)/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET (1:30 p.m. PT).

The webcast (live and archived) and related slide presentation can be accessed through <https://evofem.investorroom.com/2021Q3Results> or directly at <https://edge.media-server.com/mmc/p/xmw874kh>. Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required.

If participating by phone, please dial in approximately 15 minutes prior to the start of the call using (866) 503-5561 (U.S. toll-free) or (253) 336-2965, and referring to conference ID 7464495.

A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 7464495.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.
